CXCL12 and Miyoshi myopathy: We found that daratumumab, isatuximab (0.1 μg/mL or higher) or the combination of both inhibited CXCL12-mediated migration in two MM cell lines when compared to isotype control, and they were comparable to anti-CXCR4 positive control (Figure 3A,B).